Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05208086 | Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma(RHUMM) | active not recruiting | — | 180 | Intergroupe Francophone du MyelomeNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05572515 | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-9) | active not recruiting | Phase 3 | 614 | Janssen Research & Development, LLC |
| 24 |
| Apr 13, 2026 |
| clinicaltrials |
| NCT05955508 | A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma | active not recruiting | Phase 2 | 40 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06062537 | Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients(TEC-CARE) | active not recruiting | — | 200 | Intergroupe Francophone du MyelomeNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04911478 | Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells | active not recruiting | — | 50 | Adicet TherapeuticsINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT01054196 | Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study | active not recruiting | Phase 1 / Phase 2 | 52 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03697512 | MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas(MALIBU) | active not recruiting | Phase 2 | 175 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 5 | Apr 8, 2026 | clinicaltrials |
| NCT04404660 | A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | active not recruiting | Phase 1 / Phase 2 | 153 | Autolus LimitedINDUSTRY | 3 | Apr 8, 2026 | clinicaltrials |
| NCT05798156 | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP(R-Pola-Glo) | active not recruiting | Phase 2 | 125 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Apr 8, 2026 | clinicaltrials |
| NCT06508658 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(EPCORE DLBCL-4) | active not recruiting | Phase 3 | 379 | GenmabINDUSTRY | 28 | Apr 8, 2026 | clinicaltrials |
| NCT03240211 | Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | active not recruiting | Phase 1 | 37 | University of VirginiaOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04417166 | Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma | active not recruiting | Phase 2 | 30 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04925193 | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 2 | 18 | University of Colorado, DenverOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04646395 | Study of Acalabrutinib and Tafasitamab in MZL Patients | active not recruiting | Phase 2 | 26 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Apr 6, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT04108624 | Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients | active not recruiting | N/A | 68 | University of ChicagoOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04975997 | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(EXCALIBER-RRMM) | active not recruiting | Phase 3 | 939 | CelgeneINDUSTRY | 31 | Apr 3, 2026 | clinicaltrials |
| NCT05411497 | Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 5 | Mayo ClinicOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05393804 | A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant | active not recruiting | Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05994235 | Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma | active not recruiting | Phase 2 | 23 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07480863 | Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL | active not recruiting | Phase 2 | 65 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients(frontMIND) | active not recruiting | Phase 3 | 899 | Incyte CorporationINDUSTRY | 29 | Apr 1, 2026 | clinicaltrials |
| NCT02051257 | Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 51 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05020015 | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | active not recruiting | Phase 2 | 27 | TakedaINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04947319 | Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) | active not recruiting | Phase 2 | 119 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05160922 | Crizotinib Continuation Clinical Study | active not recruiting | Phase 4 | 27 | PfizerINDUSTRY | 5 | Mar 30, 2026 | clinicaltrials |
| NCT06090162 | LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma(SAKK 38/23) | active not recruiting | N/A | 64 | Swiss Cancer InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02682641 | Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL | active not recruiting | Phase 2 | 50 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03236428 | Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04835129 | Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma(IMPEDE) | active not recruiting | Phase 2 | 28 | Medical College of WisconsinOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06192888 | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06223516 | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 60 | AbbVieINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT03361852 | Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma | active not recruiting | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04756726 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | active not recruiting | Phase 1 | 224 | C4 Therapeutics, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04268498 | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma(ADVANCE) | active not recruiting | Phase 2 | 310 | University of MiamiOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | active not recruiting | Phase 1 / Phase 2 | 253 | Taiho Oncology, Inc.INDUSTRY | 8 | Mar 20, 2026 | clinicaltrials |
| NCT02773030 | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 466 | CelgeneINDUSTRY | 11 | Mar 20, 2026 | clinicaltrials |
| NCT02405676 | BNHL-2015 for Children or Adolescents in China(BNHL-2015) | active not recruiting | Phase 2 / Phase 3 | 200 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04726501 | CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma | active not recruiting | Phase 4 | 200 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04881838 | CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL | active not recruiting | Phase 3 | 172 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06357975 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02845882 | LBL-2016 for Children or Adolescents in China | active not recruiting | Phase 3 | 150 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04904588 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide(ACCESS) | active not recruiting | Phase 2 | 300 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04931368 | OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma(OptiMATe) | active not recruiting | Phase 3 | 331 | Klinikum StuttgartOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480837 | Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma | active not recruiting | — | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480850 | Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05257083 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma(CARTITUDE-6) | active not recruiting | Phase 3 | 759 | Stichting European Myeloma NetworkNETWORK | 16 | Mar 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 13, 2026source: clinicaltrials